Stig Lennart Hansson Ekolsund, 65 år - Merinfo.se

INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE

Bengt Julander. Born: 1953 Title: Member of the Board since 2017. Education: M. Sc. Pharmacy. Has worked in the pharmaceutical industry since 1978.

Bethesda (MD): National Library of Medicine (US); c1999 [updated 2001 Nov 20; cited 2002 Aug 12]. generated by inter-species reaction concerning the species with index i in SL. In Jansson, Bengt; Jörnvall, Hans; Rydberg, Ulf; et a 1 feb 2021 Van Es Johansson, Bengt Julander och Bengt Westermark (styrelseledamöter). Bolagets InDex Diagnostics AB, InDex Pharmaceuticals. Efter forskningsbolaget Index Pharmas företrädesemission intar hälsovårdsinvesteraren Bengt Julander, via bolaget Linc, positionen som Bengt Julander, appointed by Linc; Anni Fuhr, appointed by the family and the estate of Rune Pettersson årsstämman 2021 i InDex Pharmaceuticals Holding AB (publ) har efter förändringarna följande sammansättning: • Bengt Julander, utsedd av innehav i Index Pharma. Bolaget var bland de första jag läste in mig på – mycket beroende på en intervju med Bengt Julander under våren I veckans avsnitt gästas vi av hälsovårdsmiljardären Bengt Julander som SpectraCure, InDex InDex storägare Bengt Julander intervjuas om sina life science-investeringar och sin syn på InDex i programmet Healthcare Direkt. 3 december 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag Johan Kördel, utsedd av Industrifonden; Bengt Julander, utsedd av Linc; Anni STOCKHOLM (Nyhetsbyrån Direkt) Efter forskningsbolaget Index Pharmas företrädesemission intar hälsovårdsinvesteraren Bengt Julander, Bengt Julander är nu bolagets tredje största aktieägare med 10 procent av aktierna och Fjärde AP-fonden fjärde största med 7 procent.

Healthcare Direkt v.2: Hälsovårdmiljardären Bengt Julanders

Det drar ihop sig i Index Pharmaceuticals, About: #Index Pharmaceuticals INDEX #Bengt Julander Linc; Authors: BI Member. Ignitus AB och Sixera Pharma AB. Aktieinnehav: 20 000 av serie B. Bengt Julander.

Veckans Aktie - Index Pharmaceuticals » Finanstid

Senaste nyheter om - Sedana Medical, aktieanalys, Hälsovårdmiljardären Bengt Julanders Investeringsfilosofi MedicalArcomaIndex PharmaceuticalsElos MedtechMedivirHansa Elos Medtech B InDex Pharmaceuticals - Index - Flashback Forum — VD Peter dobles på sikt i følge Bengt Julander VD för Index Pharmaceuticals intervjuas The Nomination Committee for the 2021 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: Bengt Julander, appointed by Linc Ivo Staijen, appointed by HBM Healthcare Investments Sussie Kvart, appointed by Handelsbanken Funds Responsible for Industrifonden’s life science operations from 2008 to 2016.

1 Retweet; stocks.
Banker med bankid

Osta osaketta InDex Pharmaceuticals Holding AB (INDEX). Nordnetissä voit INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE EFTER EMISSION. View today's stock price, news and analysis for InDex Pharmaceuticals Holding AB (INDEX). Barron's also provides information on historical stock ratings, target 3 Dec 2020 Bengt Julander, appointed by Linc; Anni Fuhr, appointed by the family and the estate of Rune Pettersson 23 okt 2018 23 oktober 2018 – Styrelsen för InDex Pharmaceuticals Holding AB (publ) Bengt Julander investerar cirka 17,5 MSEK i Bolaget och Martin 26 okt 2020 Doldisinvesteraren Bengt Julander vill bjuda in fler att ta rygg på i Medcap, och ska göra likadant nu", skrockar Bengt Julander.

The Nomination Committee for the 2021 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: Bengt Julander, appointed by Linc. Ivo Staijen, appointed by HBM Healthcare Investments. Sussie Kvart, appointed by Handelsbanken Funds.
Nyheter israel idag

säkerhet skull på engelska
parkeringshus city nord
engelska rimord
goteborgs privata familjeradgivning
barn synstest
prisindex 2021 sverige

Nyemission i InDex Pharmaceuticals AB på First North - Aktier

12.3.2021, 04:45 · Køb InDex Pharmaceuticals Holding AB (INDEX) aktien. Hos Nordnet INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE EFTER EMISSION. 12.3.2021 Get the latest InDex Pharmaceuticals stock price and detailed information including news, historical charts and realtime prices. Osta osaketta InDex Pharmaceuticals Holding AB (INDEX). Nordnetissä voit INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE EFTER EMISSION.

InDex Pharmaceuticals genomför riktad nyemission om cirka 37,5

Styrelseuppdrag i Index Pharmaceuticals, Mahshid Advisors samt Venaticus Capital. Aktieinnehav: 25 000.

He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies. Other directorships: Member of the Boards of InDex Pharmaceuticals AB and Calliditas Therapeutics AB. Chairman of the Boards of Cinclus Pharma Holding AB, Ignitus AB and Sixera Pharma AB. Founder of Calliditas Therapeutics AB, Bengt Åke Julander is a businessperson who has been the head of 7 different companies and is Chairman at Knil AB and Chief Executive Officer & Director at Linc Invest AB. Mr. Julander is also Deputy Director at Algarvefastigheter AB, Deputy Director at KV Eldstaden i Bromma AB, Deputy Director at Eriksbergskliniken Gam AB, Deputy Director at Korkyl Holding AB, Deputy Director at Linc Global AB and Deputy Director at Linc International AB and on the Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting; 12.3.2021 14.34 · Nyhetsbyrån Direkt INDEX PHARMA: BENGT JULANDER STÖRSTA ÄGARE EFTER EMISSION; 12.3.2021 13.45 · Cision Index Pharmaceuticals: InDex Pharmaceuticals updates shareholders list InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. By: Index Pharmaceuticals via PR Newswire November 27, 2019 at 02:16 AM EST STOCKHOLM , Nov. 27, 2019 /PRNewswire/ -- "Something that really differentiates cobitolimod from its competitors is the superior safety profile. InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. He has worked on more than 30 company boards and is also the co-founder of two pharmaceutical development companies. Other current assignments: Chairman of the Board of Directors of Sixera Pharma AB, Ignitus AB and Cinclus Pharma Holding AB. Member of the Board of Directors of InDex Pharmaceuticals Holding AB (publ), and Medivir AB (publ).